Clinical trials: Neuroendocrine Cancer
Non Small Cell Lung Cancer, Metastatic Melanoma
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
This is a phase I/II study that will evaluate the safety and toxicity of this combinatorial approach. Eligible patients >18 years of age with histologically proven metastatic NSCLC, melanoma, RCC, or HNSCC who have failed PD-1 /…
- Conditions
- Non Small Cell Lung Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03474497
- Testing
- IL-2, Pembrolizumab, Radiotherapy
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Megan Daly, MD
Metastatic Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7
CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma
This phase II trial studies the side effects and how well white blood cells taken from person's own (autologous) cluster of differentiation (CD)8+ antigen-specific T cells, cyclophosphamide, aldesleukin, and ipilimumab work in…
- Trial name
- NCT02027935
- Testing
- Aldesleukin, Autologous CD8+ Melanoma Specific T Cells, Cyclophosphamide
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma, Gastrointestinal Cancer
Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer
Background: Exomes are the parts of deoxyribonucleic acid (DNA) that make proteins. Researchers are finding a way to read the letters in the exome. Incorrect letters are called mutations. Tumors contain specific mutations.
- Conditions
- Melanoma, Gastrointestinal Cancer, Breast Cancer, Ovarian Cancer
- Trial name
- NCT03300843
- Testing
- Peptide loaded dendritic cell vaccine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Melanoma
Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention
This study is designed to evaluate the safety and tolerability of treatment with oral microbiome study intervention (SER-401) or matching placebo in combination with anti-programmed cell death 1 (anti-PD-1) therapy (nivolumab) in…
- Trial name
- MCGRAW (NCT03817125)
- Testing
- Vancomycin pretreatment, Nivolumab, SER-401
- Where
- 7 sites in United States
- Volunteers
- 14 people
- Sponsor
- Parker Institute for Cancer Immunotherapy
N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
This is a Phase 2, multicenter, randomized, controlled, open-label trial of pimasertib versus dacarbazine aimed to confirm the activity of pimasertib in previously untreated subjects with N-Ras mutated locally advanced or…
- Trial name
- NCT01693068
- Testing
- Pimasertib, Dacarbazine
- Where
- 101 sites in United States, Australia and 12 more
- Volunteers
- 194 people
- Sponsor
- EMD Serono
Metastatic Melanoma
Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma
Prospective, interventional multicenter study evaluating adoptive cell therapy (ACT) via infusion of LN-144 (autologous TIL) followed by interleukin 2 (IL-2) after a nonmyeloablative lymphodepletion (NMA LD) preconditioning…
- Trial name
- LN-144 (NCT02360579)
- Testing
- Lifileucel
- Where
- 57 sites in United States, France and 6 more
- Volunteers
- 220 people
- Sponsor
- Iovance Biotherapeutics, Inc.
Uveal Melanoma
A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma
IMCgp100-102 is a Phase I/II study of the weekly intra-patient escalation dose regimen with IMCgp100 as a single agent in participants with metastatic uveal melanoma (mUM).
- Trial name
- NCT02570308
- Testing
- IMCgp100
- Where
- 26 sites in United States, Canada and 3 more
- Volunteers
- 146 people
- Sponsor
- Immunocore Ltd
Carcinoid Tumors
Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors
Study evaluating SOM230 in patients with metastatic carcinoid tumors
- Trial name
- NCT00088595
- Testing
- Pasireotide (SOM230)
- Where
- 4 sites in United States
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Papillary Carcinoma of Thyroid Gland, Metastatic Medullary Thyroid Cancer
Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study
The purpose of this research study is to see if a specific kind of MRI can identify small and otherwise undetected abnormal lymph nodes in patients with thyroid cancer who are undergoing surgery.
- Conditions
- Papillary Carcinoma of Thyroid Gland, Metastatic Medullary Thyroid Cancer, Follicular Thyroid Cancer Lymph Node Metastasis
- Trial name
- NCT01927887
- Testing
- Ferumoxytol, Nanoparticle MRI
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Massachusetts General Hospital
Pancreatic Neuroendocrine Tumor, Well Differentiated and Progressive
OPALINE : A Study Of Morbidity And Mortality At 2 Years
A descriptive, prospective (partly retrospective), multisite, observational study conducted in France in adult patients treated for a well differentiated, unresectable or metastatic, pancreatic neuroendocrine tumor with disease…
- Trial name
- OPALINE (NCT02264665)
- Testing
- sunitinib, everolimus, chemotherapies recommended in france
- Where
- 35 sites in France
- Volunteers
- 144 people
- Sponsor
- Pfizer
Uveal Melanoma
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
To evaluate the overall survival of HLA-A*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investigator's Choice of dacarbazine, ipilimumab, or pembrolizumab.
- Trial name
- NCT03070392
- Testing
- IMCgp100, Dacarbazine, Ipilimumab
- Where
- 57 sites in United States, Australia and 12 more
- Volunteers
- 378 people
- Sponsor
- Immunocore Ltd
Neuroendocrine Tumors, Neuroendocrine Carcinoma
Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
The purpose of this study is to: Assess overall radiographic response rate (ORR) Assess progression-free survival (PFS) Test the safety and tolerability of Pembrolizumab in combination with lenvatinib
- Conditions
- Neuroendocrine Tumors, Neuroendocrine Carcinoma, Neuroendocrine Cancer
- Trial name
- NCT03290079
- Testing
- Pembrolizumab, Lenvatinib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
This randomized phase III trial studies how well pembrolizumab works compared with the current standard of care, physician/patient choice of either high-dose recombinant interferon alfa-2B or ipilimumab, in treating patients with…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Mucosal Melanoma
- Trial name
- NCT02506153
- Testing
- Biospecimen Collection, Computed Tomography, Ipilimumab
- Where
- 576 sites in United States, Canada and 1 more
- Volunteers
- 1,301 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants…
- Conditions
- Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
- Trial name
- LIBRETTO-001 (NCT03157128)
- Testing
- LOXO-292
- Where
- 85 sites in United States, Australia and 14 more
- Volunteers
- 857 people
- Sponsor
- Eli Lilly and Company
Cutaneous Melanoma
Enhancing Skin Cancer Early Detection and Treatment in Primary Care
Skin cancer screening may help find melanoma sooner, when it may be easier to treat. If found early melanoma and other types of skin cancer may be curable.
- Trial name
- NCT05675709
- Testing
- Training and Education
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- OHSU Knight Cancer Institute
Melanoma, Sentinel Node
Infrared Lymphangiography as a Method of Sentinel Node Identification
The initial treatment for most people with melanoma involves wide excision of the skin and sentinel node biopsy. As with other cancers, the status of the sentinel node provides important prognostic information to the patient and…
- Trial name
- SPY-SN (NCT02057393)
- Testing
- Indocyanine green, Technetium99, Methylene blue
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Milton S. Hershey Medical Center
Neurofibromatosis Type II
Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2
This trial studies whether Everolimus is efficacious in treating neurofibromatosis 2.
- Trial name
- NCT01419639
- Testing
- Everolimus (RAD001) , Afinitor®
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- NYU Langone Health
Gastrinoma, Glucagonoma
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
This phase II trial is studying how well sorafenib tosylate works in treating patients with progressive metastatic neuroendocrine tumors.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT00131911
- Testing
- sorafenib tosylate
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
This phase I/IIa trial studies the side effects and best dose of gene-modified T cells when given with or without decitabine, and to see how well they work in treating patients with malignancies expressing cancer-testis antigens…
- Conditions
- Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Ovarian Carcinoma
- Trial name
- NCT02650986
- Testing
- Cyclophosphamide, Decitabine, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Roswell Park Cancer Institute
Recurrent Melanoma, Stage IIIB Melanoma
Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations
This phase II trial studies trametinib in treating patients with melanoma with v-Raf murine sarcoma viral oncogene homolog B (BRAF) non-V600 mutations that has spread to other places in the body.
- Conditions
- Recurrent Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
- Trial name
- NCT02296112
- Testing
- trametinib, laboratory biomarker analysis, pharmacological study
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Vanderbilt-Ingram Cancer Center